Abstract
Initiatives such as The Cancer Genome Atlas and the International Cancer Genome Consortium has led to the identification of specific molecular drivers of human tumours. This in turn has led to therapy focused on targeting drivers responsible for tumour growth, irrespective of the specific histological type of cancer. Two studies published in The Lancet Diabetes and Endocrinology1 by Vivek Subbiah and colleagues and The Lancet Oncology2 by Justin F Gainor and colleagues, are great examples of such an approach.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
